DMC recommends Emisphere Technologies' to proceed with oral calcitonin trial for OP and OA

Emisphere Technologies, Inc. (OTC BB:EMIS) today announced that an independent Data Monitoring Committee (“DMC”) informed Novartis and its partner Nordic Bioscience about their recommendation to proceed with the Osteoporosis (“OP”) Phase 3 Study 2303 and the Osteoarthritis (“OA”) Phase 3 Study 2301 exploring the safety and efficacy of an oral formulation of salmon calcitonin to treat patients with osteoporosis and osteoarthritis of the knee.

This recommendation is based on a futility analysis of one-year data for all patients enrolled in the study for 12 months and includes both an assessment of safety and efficacy parameters.